506108927 06/16/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6155649

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
HOWARD HUGHES MEDICAL INSTITUTE	07/30/2019

RECEIVING PARTY DATA

Name:	MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Street Address:	77 MASSACHUSETTS AVENUE
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16449100

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: heather@pabstpatent.com

Correspondent Name: PABST PATENT GROUP LLP

Address Line 1: 1545 PEACHTREE STREET, SUITE 320

Address Line 4: ATLANTA, GEORGIA 30309

ATTORNEY DOCKET NUMBER:	MIT 20602
NAME OF SUBMITTER:	HEATHER BIFFLE
SIGNATURE:	/Heather Biffle/
DATE SIGNED:	06/16/2020

Total Attachments: 4

source=Executed Assignment - HHMI to MIT#page1.tif source=Executed Assignment - HHMI to MIT#page2.tif source=Executed Assignment - HHMI to MIT#page3.tif source=Executed Assignment - HHMI to MIT#page4.tif

PATENT 506108927 REEL: 052951 FRAME: 0144

ASSIGNMENT

WHEREAS, HOWARD HUGHES MEDICAL INSTITUTE of 4000 Jones Bridge Road, Chevy Chase, Maryland 20815-6789 (hereinafter said "Assignor") is owner of a joint and undivided interest in (1) a certain invention(s) and/or improvement(s) in "METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT" described in U.S. Application No. 16/449,100 filed in the United States Patent and Trademark Office on June 21, 2019, by Chengcheng Jin, Georgia Lagoudas, Paul Blainey, and Tyler Jacks, and in U.S. Provisional Application No. 62/769,215 filed in the United States Patent and Trademark Office on November 19, 2018, and in U.S. Provisional Application No. 62/727,955 filed in the United States Patent and Trademark Office on September 6, 2018, by Chengcheng Jin, Georgia Lagoudas, and Tyler Jacks, (2) U.S. Application No. 16/449,100 filed on June 21, 2019, U.S. Provisional Application No. 62/769,215 filed November 19, 2018, and U.S. Provisional Application No. 62/727,955 filed September 6, 2018, (3) all Letters Patent of the United States and its possessions and territories and of all foreign countries and jurisdictions which may or shall be granted on said invention(s), on said improvement(s), or on said application(s), (4) all provisional, divisional, continuation, reissue, PCT, national phase, or other applications based thereon, and (5) all rights of priority, including the right to claim priority to said application(s), under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and any other treaty relating thereto;

WHEREAS, Tyler Jacks has been appointed to act as ASSIGNOR's agent for the purpose of assigning the rights ASSIGNOR has in (1) a certain invention(s) and/or improvement(s) in "METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT"

45326347 1 MIT 20602

described in U.S. Application No. 16/449,100 filed in the United States Patent and Trademark Office on June 21, 2019, by Chengcheng Jin, Georgia Lagoudas, Paul Blainey, and Tyler Jacks, and in U.S. Provisional Application No. 62/769,215 filed in the United States Patent and Trademark Office on November 19, 2018, and in U.S. Provisional Application No. 62/727,955 filed in the United States Patent and Trademark Office on September 6, 2018, by Chengcheng Jin, Georgia Lagoudas, and Tyler Jacks, (2) U.S. Application No. 16/449,100 filed June 21, 2019, U.S. Provisional Application No. 62/769,215 filed November 19, 2018, and U.S. Provisional Application No. 62/727,955 filed September 6, 2018, (3) all Letters Patent of the United States and its possessions and territories and of all foreign countries and jurisdictions which may or shall be granted on said invention(s), on said improvement(s), or on said application(s), (4) all provisional, divisional, continuation, reissue, PCT, national phase, or other applications based thereon, and (5) all rights of priority, including the right to claim priority to said application(s), under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and any other treaty relating thereto:

WHEREAS, Tyler Jacks, for myself and acting as agent for ASSIGNOR, for good and valuable consideration from Massachusetts Institute of Technology having its principal place of business at 77 Massachusetts Avenue, Cambridge, Massachusetts 02319 (hereinafter said "Assignee"), the receipt of which is hereby acknowledged, does sell, assign and transfer, for myself and as agent for the Howard Hughes Medical Institute, unto said Assignee, its successors and assigns, its entire right, title and interest for the United States of America, and its territories and all foreign countries and jurisdictions, including all rights of priority under the International Convention for the Protection of Industrial Property, in (1) a certain invention(s) and/or improvement(s) in "METHODS AND COMPOSITIONS TARGETING LUNG MICROBIOTA

45326347 2 MIT 20602

AND ITS RESPONDING IMMUNE PATHWAYS FOR LUNG CANCER TREATMENT" described in U.S. Application No. 16/449,100 filed in the United States Patent and Trademark Office on June 21, 2019, by Chengcheng Jin, Georgia Lagoudas, Paul Blainey, and Tyler Jacks, and in U.S. Provisional Application No. 62/769,215 filed in the United States Patent and Trademark Office on November 19, 2018, and in U.S. Provisional Application No. 62/727,955 filed in the United States Patent and Trademark Office on September 6, 2018, by Chengcheng Jin, Georgia Lagoudas, and Tyler Jacks, (2) U.S. Application No. 16/449,100 filed June 21, 2019, U.S. Provisional Application No. 62/769,215 filed November 19, 2018, and U.S. Provisional Application No. 62/727,955 filed September 6, 2018, (3) all Letters Patent of the United States and its possessions and territories and of all foreign countries and jurisdictions which may or shall be granted on said invention(s), on said improvement(s), or on said application(s), (4) all provisional, divisional, continuation, reissue, PCT, national phase, or other applications based thereon, and (5) all rights of priority, including the right to claim priority to said application(s), under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and any other treaty relating thereto:

AND, said Assignor hereby binds itself, its legal representatives and assigns properly to execute without further consideration any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect, the sale, assignment, transfer and conveyance hereby made or intended to be made and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and its territories and in all other foreign countries and jurisdictions to said Assignee, with specifications and claims in such form as shall be approved by the counsel of said Assignee, and to vest and confirm in said Assignee, their successors and assigns, the legal title to all such patents.

[Signatures on following page]

3 45326347 MIT 20602 701350/00797

	IN WITNESS WHEREOF, I have executed this Assignment this 30 day
of	July , 20 19.
	HOWARD HUGHES MEDICAL INSTITUTE
	Ву:
	Tyler Jacks, for himself and as agent for the Howard Hughes Medical Institute
	Title: Agent for Howard Hughes Medical Institute
Witnes	eses:
1.	Signed: Judy a. Lu
	Printed Name: Judy A. Teixeiva
	Address: 70 Briarwood Rd
	Tewksbury MA 01876
2.	Signed: Caus Gel
	Printed Name: Karen Yee
	Address: 176 West Brookline Street
	Boston, MA 02118

45326347

MIT 20602 701350/00797